Type of hormone therapy and risk of misclassification at mammography screening

TY - JOUR

T1 - Type of hormone therapy and risk of misclassification at mammography screening

AU - Njor, Sisse H

AU - Hallas, Jesper

AU - Schwartz, Walter

AU - Lynge, Elsebeth

AU - Pedersen, Anette Tønnes

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Objective: Current users of hormone therapy (HT) are known to have a lower accuracy of mammography screening than do never users. We studied whether the risk of misclassification depends on type of hormone, administration, regimen, and dose of the therapy. Methods: We linked data from mammography screening registers with drug prescription registers from Fyn, Denmark to identify current and never HT users among screening participants. We compared false-positive risks and interval cancer proportions between current users of different HT preparations, taking women's age, breast density, screen number, and age of comparison mammogram into account. Results: Estrogen therapy users had a significantly higher false-positive risk when the administration was by injection instead of oral (relative risk [RR], 2.37; 95% CI, 1.37-4.09). Women using sequential estrogen plus progestogen therapy had a significantly higher false-positive risk (RR, 1.94; 95% CI, 1.16-3.26) and a nonsignificantly higher interval cancer proportion (RR, 4.29; 95% CI, 0.69-26.53) when the administration of both hormones was transdermal instead of oral. Using tibolone instead of comparable hormones gave a nonsignificantly lower false-positive risk and a nonsignificantly higher interval cancer proportion. Conclusions: Our data showed increased risks of misclassification at mammography screening among women using estrogen injections or transdermal, sequential estrogen plus progestogen. Tibolone seems to offer no advantage regarding accuracy of screening mammography.

AB - Objective: Current users of hormone therapy (HT) are known to have a lower accuracy of mammography screening than do never users. We studied whether the risk of misclassification depends on type of hormone, administration, regimen, and dose of the therapy. Methods: We linked data from mammography screening registers with drug prescription registers from Fyn, Denmark to identify current and never HT users among screening participants. We compared false-positive risks and interval cancer proportions between current users of different HT preparations, taking women's age, breast density, screen number, and age of comparison mammogram into account. Results: Estrogen therapy users had a significantly higher false-positive risk when the administration was by injection instead of oral (relative risk [RR], 2.37; 95% CI, 1.37-4.09). Women using sequential estrogen plus progestogen therapy had a significantly higher false-positive risk (RR, 1.94; 95% CI, 1.16-3.26) and a nonsignificantly higher interval cancer proportion (RR, 4.29; 95% CI, 0.69-26.53) when the administration of both hormones was transdermal instead of oral. Using tibolone instead of comparable hormones gave a nonsignificantly lower false-positive risk and a nonsignificantly higher interval cancer proportion. Conclusions: Our data showed increased risks of misclassification at mammography screening among women using estrogen injections or transdermal, sequential estrogen plus progestogen. Tibolone seems to offer no advantage regarding accuracy of screening mammography.

KW - Aged

KW - Breast Neoplasms

KW - Carcinoma

KW - Denmark

KW - Diagnostic Errors

KW - Early Detection of Cancer

KW - Female

KW - Hormone Replacement Therapy

KW - Humans

KW - Mammography

KW - Mass Screening

KW - Middle Aged

KW - Risk

KW - Treatment Outcome

U2 - 10.1097/gme.0b013e3181ea1fd5

DO - 10.1097/gme.0b013e3181ea1fd5

M3 - Journal article

C2 - 20729766

SN - 1072-3714

VL - 18

SP - 171

EP - 177

JO - Menopause

JF - Menopause

IS - 2

ER -